Truscreen Issues 149 Million Shares at NZ$0.013 Each

Significant Share Expansion Completed

Truscreen Group Limited (NZX:TRU) has completed a substantial capital raise through the issuance of 149,464,986 ordinary shares at NZ$0.013 each. This issuance represents a 17.4% increase in the company's total ordinary shares, which now stand at 1,006,790,307. The new shares were fully paid in cash and rank equally with existing shares, reinforcing the company’s equity base.

Rights Issue Execution and Board Approval

The shares were issued pursuant to a renounceable rights issue, a method that typically offers existing shareholders the opportunity to purchase additional shares, often at a discount, before the offer is opened to the wider market. The issuance was authorised by a resolution of Truscreen’s board of directors, ensuring compliance with NZX Listing Rules. The capital injection was announced on 30 June 2026, aligning with the company’s previously disclosed capital raising strategy.

Context of Capital Raising Amid Growth Strategy

This rights issue forms part of Truscreen’s broader efforts to secure funding for its global expansion in cervical screening technology. The company has been actively pursuing growth in emerging markets, with recent reports highlighting a 42% increase in product sales for FY2026 and initiatives including large-scale screening programs and regulatory submissions across Asia and Africa. The fresh capital is expected to support these strategic priorities, although the filing does not specify the exact allocation of proceeds.

Shareholder Impact and Market Considerations

While the capital raise strengthens Truscreen’s financial position, the 17.4% increase in shares outstanding will dilute existing shareholders' stakes unless they participated in the rights issue. The shares issued carry no special restrictions and rank equally, preserving shareholder rights on a per-share basis. Investors will be watching how this expanded capital base translates into operational progress and revenue growth, especially given the company’s recent NZ$2.25 million loss and ongoing cash burn challenges.

Next Steps for Investors

Truscreen’s announcement references a prior NZX/ASX communication from 21 May 2026, which likely contains fuller details on the rights issue terms and intended use of funds. Market participants may seek clarity on how the capital will be deployed to accelerate the company’s ambitious expansion plans and address its financial sustainability. The company’s execution on these fronts will be critical to watch in the coming quarters.